GlassScriptPhysician profile
Aida Soriano
NPI 1043281124
$7,825.17
in general payments reported to CMS, 2019-2025
29 companies · $16.00 in 2025
The $16.00 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,158 · 2020: $1,818 · 2021: $2,527 · 2022: $1,307 · 2025: $16.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,500.04 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $1,284.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $885.59 | 2019-2022 | |
| Mylan Specialty L.P. | $479.98 | 2019-2022 | |
| Grifols USA, LLC | $454.07 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $414.48 | 2019-2022 | |
| Genzyme Corporation | $402.11 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $381.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $345.97 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $243.25 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $236.08 | 2019-2022 | |
| Genentech USA, INC. | $160.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $143.68 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $138.53 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.78 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $117.70 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $82.09 | 2019-2022 | |
| Pulmonx Corporation | $63.26 | 2021-2022 | |
| Philips North America LLC | $47.45 | 2019-2021 | |
| Circassia INC. | $46.09 | 2019 | |
| United Therapeutics Corporation | $43.93 | 2021-2022 | |
| Pfizer INC. | $42.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $41.93 | 2019-2022 | |
| Shire North American Group INC | $40.23 | 2019 | |
| Amgen INC. | $29.76 | 2022 | |
| Insmed, INC. | $29.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.06 | 2019 | |
| Csl Behring | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Soriano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.